桂枝茯苓片联合头孢曲松治疗慢性盆腔炎的临床研究

目的 探讨桂枝茯苓片联合头孢曲松治疗慢性盆腔炎的临床疗效。方法 选取2020年2月—2023年1月陕西省中医医院收治的94例慢性盆腔炎患者,按随机数字表法将所有患者分为对照组和治疗组,每组各47例。所有患者于月经结束3 d后给药。对照组静脉滴注注射用头孢曲松钠,将2.0 g充分溶解于250 mL生理盐水,1次/d。治疗组在对照组基础上口服桂枝茯苓片,3片/次,3次/d。两组疗程均为14 d。观察两组的临床疗效,比较治疗前后两组症状、体征、辅助检查积分及盆腔包块最大径、症状自评量表（SCL-90）评分、世界卫生组织生活质量测定简表（WHOQOL-BREF）评分和红细胞沉降率（ESR）、中性粒细胞与淋巴细胞比值（NLR）、C反应蛋白（CRP）水平。结果 治疗后,治疗组总有效率为95.74%,显著高于对照组的82.98%（P＜0.05）。治疗后,两组患者主症、次症、盆腔局部体征、辅助检查积分及其总积分均显著降低（P＜0.05）;且均以治疗组降低更显著（P＜0.05）。治疗后,两组盆腔包块最大径和SCL-90评分均显著降低,而WHOQOL-BREF评分均显著增加（P＜0.05）;且以上评分均以治疗组改善更显著（P＜0.05）。治疗后,两组ESR、NLR、CRP水平均显著下降（P＜0.05）;治疗后,治疗组ESR、NLR、CRP水平均显著低于对照组（P＜0.05）。结论 桂枝茯苓片联合头孢曲松治疗慢性盆腔炎的整体效果确切,患者可有效获得症状体征的明显减轻,促进盆腔包块缩小及身心健康、生活质量的改善,调节机体血液流变学及炎症状态,值得临床推广应用。

Clinical study on Guizhi Fuling Tablets combined with ceftriaxone in treatment of chronic pelvic inflammation disease

Objective To explore the clinical efficacy of Guizhi Fuling Tablets combined with ceftriaxone in treatment of chronic pelvic inflammatory disease. Methods 94 Patients with chronic pelvic inflammatory disease treated in Shaanxi Provincial Hospital of Traditional Chinese Medicine from February 2020 to January 2023 were selected and divided into control group and treatment group according to random number table method, with 47 cases in each group. All patients were given the drug 3 d after the end of menstruation. Patients in the control group were iv administered with Ceftriaxone Sodium for injection, 2.0 g was fully dissolve in 250 mL normal saline, once daily. Patients in the treatment group were po administered with Guizhi Fuling Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, symptoms, signs, auxiliary examination scores, maximum diameter of pelvic masses, Symptom Checklist 90 (SCL-90) scores, World Health Organization Quality of Life Brief (WHO QOL BREF) scores, erythrocyte sedimentation rate (ESR), neutrophil to lymphocyte ratio (NLR), and C-reactive protein (CRP) levels between the two groups before and after treatment were compared. Results After treatment, the total effective rate of treatment group was 95.74%, which was significantly higher than that of control group (82.98%) (P< 0.05). After treatment, the main disease, secondary disease, local pelvic signs, auxiliary examination scores and total scores were significantly decreased in both groups (P < 0.05). The decrease was more significant in the treatment group (P < 0.05). After treatment, the maximum diameter of pelvic mass and SCL-90 score were significantly decreased, while WHOQOL-BREF score was significantly increased in both groups (P < 0.05). The improvement was more significant in the treatment group (P < 0.05). After treatment, the levels of ESR, NLR and CRP in both groups were significantly decreased (P < 0.05). After treatment, the levels of ESR, NLR and CRP in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Guizhi Fuling Tablets combined with ceftriaxone has a definite overall effect in treatment of chronic pelvic inflammation disease, and patients can effectively obtain significant reduction of symptoms and signs, promote the shrinkage of pelvic mass, improve physical and mental health, quality of life, regulate the hemorheology and inflammation state, which is worthy of clinical promotion and application.